Predicted protein targets (top 9)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | CNR1 | P21554 | 7/20 | 0.49 |
| ▸ | CNR2 | P34972 | 4/20 | 0.49 |
| ▸ | GABBR2 | O75899 | 7/20 | 0.42 |
| ▸ | GABBR1 | Q9UBS5 | 7/20 | 0.42 |
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.39 |
| ▸ | RAB9A | P51151 | 1/20 | 0.39 |
| ▸ | TDP1 | Q9NUW8 | 1/20 | 0.39 |
| ▸ | DPP4 | P27487 | 1/20 | 0.39 |
| ▸ | LMNA | P02545 | 1/20 | 0.38 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL5037353 | 1.00 | CNR1 (0.49) | CNR1CNR2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL5038491 | 0.92 | CNR1 (0.57) | CNR1CNR2ALDH1A1RAB9ATDP1 | |
| SCHEMBL5038531 | 0.92 | CNR1 (0.57) | CNR1CNR2ALDH1A1RAB9ATDP1 | |
| SCHEMBL5038488 | 0.92 | CNR1 (0.57) | CNR1CNR2ALDH1A1RAB9ATDP1 | |
| SCHEMBL5043746 | 0.83 | CNR1 (0.58) | CNR1CNR2RAB9A | |
| SCHEMBL5043872 | 0.81 | CNR2 (0.49) | CNR1CNR2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL5043874 | 0.81 | CNR2 (0.49) | CNR1CNR2GABBR2GABBR1ALDH1A1 | |
| SCHEMBL5043666 | 0.78 | CNR1 (0.56) | CNR1CNR2DPP4LMNA | |
| SCHEMBL5043793 | 0.77 | CNR1 (0.61) | CNR1CNR2 | |
| SCHEMBL762420 | 0.76 | CNR1 (0.84) | CNR1CNR2 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 4 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-7342032-B2 | Thiazole derivatives having CB1-antagonistic, agonistic or partial agonistic activity | SOLVAY PHARMACEUTICALS, INC. (NL) | 2008-03-11 | — | — | US | disclosed |
| EP-1492779-A1 | THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY | Solvay Pharmaceuticals B.V. (NL) | 2005-01-05 | — | — | EP | disclosed |
| US-20040266841-A1 | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | ABBVIE B.V. (NL) | 2004-12-30 | — | — | US | disclosed |
| WO-2003078413-A1 | THIAZOLE DERIVATIVES HAVING CB1-ANTAGONISTIC, AGONISTIC OR PARTIAL AGONISTIC ACTIVITY | SOLVAY PHARMACEUTICALS B.V. (NL) | 2003-09-25 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20040266841-A1 | Thiazole derivatives having cb1-antagonistic, agonistic or partial agonistic activity | CNR1, CNR2, CCKAR | CNR1 1/4885CNR2 2/4885GABBR2 341/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.